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Schistosomiasis is a major health problem and, despite decades of research, only one effective drug,
Praziquantel is currently available. Recent expansion of sequence databases on Schistosomamansoni and
S. japonicum has permitted a wealth of novel proteomic studies on several aspects of the organization
and development of the parasite in the human host. This unprecedented accumulation of molecular
data is allowing a more rational approach to propose drug targets and vaccine candidates, such as
proteins located at the parasite surface. Successful preliminary trials of two vaccine candidates that have
been detected at the parasite surface by proteomics give grounds for believing that such an approach
may provide a fresh start for the field.
Introduction
Schistosomes are blood-dwelling trematode parasites and the cau-
sative agents of schistosomiasis, a tropical disease affecting 200
million individuals, being endemic in 74 countries in tropical
regions of Africa, Asia and South America [1]. It is not totally
understood how the parasite succeeds in escaping the host
immune system, giving rise to chronic infections possibly persist-
ing for decades. Considering that scenario, development of new
treatments for schistosomiasis would benefit millions of people
living in developing countries.
Despite the testing of drugs from different classes over the past
decades [2], Praziquantel remains the strategic cornerstone for the
treatment of schistosomiasis worldwide, which heavily relies on
massive chemotherapy [3]. Praziquantel is effective against all
Schistosoma species infecting humans, has been extensively
tested, does not display severe side effects and is currently inex-
pensive and available [4,5].
Reports of treatment failure in Senegal and Egypt [6,7], where
isolates with reduced susceptibility to Praziquantel were obtained,
have raised concerns about development of drug resistance.
Further in vitro experiments confirmed the development of para-
site resistance to Praziquantel compared with susceptible isolates
[8–11]. It is still controversial whether the low cure rates observed
can be correlated with the emergence of Praziquantel-resistant
parasites, because the interpretation of data is complicated by
other factors, such as reinfection of patients in the field, varying
sensitivity of diagnostics techniques utilized and the presence of
non-susceptible immature worms in the patients [12,13]. Despite
these uncertainties, development of novel, effective drugs against
schistosomiasis is presently needed to provide a range of treat-
ments using different drug classes [3].
In addition, there is currently no effective vaccine against
schistosomiasis; considering the peculiarities of schistosome infec-
tion, even the development of vaccines that partially diminish the
worm burden or female fecundity could have a significant impact
on the control of the disease. Several candidates have been pro-
posed in the 1980s and 1990s. Their discoverywas basedmainly on
the recognition of these proteins by protective antibodies/serum
or high immunogenicity [14–19]. Despite promising preliminary
results, tests with six selected antigens (glutathione-S-transferase
(SmGST), triose phosphate isomerase (TPI), paramyosin, 23 kDa
integral membrane tetraspanin protein (Sm23), myosin heavy
chain (IrV5) and 14 kDa fatty acid binding protein (Sm14)) by
independently contracted laboratories in the Schistosomamansoni/
mouse experimental system showed disappointing results [20]. In
addition, all these antigens, with the exception of Sm23, are not
expected to display an extracellular location and are instead
cytosolic or cytoskeletal components, which raises doubts about
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the mechanisms of how they trigger the immune effector system
[21]. Currently, Phase I and II clinical trials in humans are under-
way using S. hematobium glutathione-S-transferase; on the basis of
previous results it is hoped that vaccination with this antigen
should help to limit pathology and improve the efficiency of
Praziquantel [22].
It is clear that development of new drugs and vaccines for schis-
tosomiasis would provide important alternatives for Praziquantel
treatment. New drugs would permit combined treatments to
increase the efficacy of Praziquantel or alternate treatments that
wouldavoiddevelopmentof resistance.Developmentofaneffective
vaccine would be quite desirable since, unlike chemotherapies, it
mightprovidelonger termprotection.Therefore,drugsandvaccines
appear to be complementary to each other and strategies to stop
the dissemination of the disease may involve both components.
New opportunities generated by the recent expansion
of schistosome molecular databases
Improvement of the Sanger DNA-sequencing technique during
the 1990s allowed its automation and the development of several
strategies for high-throughput sampling of DNA and cDNA, result-
ing in an exponential increase in the number of sequences depos-
ited in public databases. The use of such strategies permitted the
intensive sequencing of schistosomes’ genome and transcriptome
over the past few years and has greatly influenced the approaches
employed to understand parasite biology. Two large-scale, inde-
pendent, sequencing projects on S. mansoni and japonicum tran-
scriptomes [23,24] allowed, for the first time, a broad sampling of
components from the parasites’ molecular systems. Analysis of the
gene collection represented by the ESTs is based on the inferred
functions, which are deduced from alignments of the predicted
protein products with proteins of known function from other
organisms. Such analyses have allowed the proposal of an initial
list with several vaccine and drug target candidates [23]. More
recently, a draft of the S. mansoni genome has been made publicly
available and is currently being annotated [25]. The combination
of transcriptome and genome data allows a comprehensive
description of the schistosome genes and provides an invaluable
repository for further studies.
In fact, the availability of schistosome large-scale sequencing
data in conjunction with technical advances is permitting a series
of post-genomic experiments aimed at better understanding the
parasite biology and searching for genes that are crucial for parasite
development, differentiation and parasitism. Microarray plat-
forms with oligonucleotide probes designed from the transcrip-
tome sequencing data allowmonitoring of the expression of a very
large fraction of the parasite genes [26]. Silencing of those newly
described schistosome genes is now possible with the demonstra-
tion of its feasibility using RNAi technology [27,28] that provides a
way of inferring function, even for schistosome-specific genes that
do not have any known ortholog genes.
Proteomics also benefited from the expansion of schistosome
databases concomitantly with the improvement of technology.
Since no organisms phylogenetically close to schistosomes have
been extensively sequenced, only a small portion of schistosome
proteins are expected to have the high degree of identity with non-
schistosome protein sequences in the public databases. Therefore,
before large-scale sequencing of the parasites’ transcriptomes a
considerable number of spectra generated bymass spectrometry of
schistosome peptides could not be reliably associated with an
orthologous protein from public databases. In that scenario, gen-
eration of large databases of schistosome coding sequences [23,24]
has greatly improved the level of identification in proteomic
studies of these organisms.
In fact, several proteomics studies have used EST assemblies, or
gene prediction data based on the genome, for peptide searches
[29–32] or have used full-length clones of schistosome genes that
resulted from further transcriptome sequencing [33]. Using these
resources, several strategies have been employed to search for
potential novel vaccines and drug targets, as we will describe in
detail in the next sections and is summarized in Table 1.
Selecting vaccine candidates using data from high
throughput studies
Expansion of the molecular databases referred to in the previous
sections should, in principle, permit the use of a novel approach
for identification of vaccine targets, termed reverse vaccinology. It
consists of in silico analysis of genomes from pathogens to select
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TABLE 1
Summary of different aspects approached by proteomic studies with potential implication for the development of schistosomiasis
therapies.
Characteristics studied Life stages sampleda Organism References
Proteins expressed in different life cycle stages c, s, a, e Schistosoma mansoni [42]
Proteins expressed in different life cycle stages c, s, a, e, l Schistosoma japonicum [33]
Proteins differentially expressed between genders am, af Schistosoma japonicum [43]
Proteins differentially expressed between adult worm tegument and carcass a Schistosoma mansoni [30]
Proteins present at different fractions of the adult worm tegument a Schistosoma mansoni [29]
Proteins exposed at adult worm surface a Schistosoma mansoni [47]
Protein content of adult and schistosomule tegument s, e Schistosoma japonicum [33]
Protein content of adult tegument a Schistosoma bovis [50]
Proteins exposed at adult worm surface a Schistosoma bovis [51]
Host proteins present in parasite tissue c, s, a, e, l Schistosoma japonicum [52]
Host proteins present in parasite tissue a, e Schistosoma mansoni [47,53]
Cercarial secretions c Schistosoma mansoni [31,55,57]
Cercarial secretions c Schistosoma japonicum [56]
Egg secretions e Schistosoma mansoni [32]
Larval secretions l Schistosoma mansoni [54]
a c, cercaria; s, schistosomulum; a, adult worm; am, male adult worm; af, female adult worm; e, egg, l, miracidium (larva).
www.drugdiscoverytoday.com 473
R
ev
ie
w
s
 G
E
N
E
T
O
S
C
R
E
E
N
ORFs encoding potentially antigenic exposed proteins, followed
by large-scale screening of these antigens in immunization pro-
tocols using recombinant expression [34]. This high throughput
approach has been successfully used to propose promising vaccine
targets for prokaryote pathogens such as Neisseria meningitides [35]
and Streptococcus agalactiae [36]. Reverse vaccinology has also been
used for identifying potential vaccine candidates in the protozoa
Trypanosoma cruzi and Leishmania [37–39]. Use of this approach in
more complex eukaryotic pathogens such as schistosomes, how-
ever, suffers from several drawbacks: (1) deduction of ORFs from
genomes of most eukaryotes is not straightforward owing to
mRNA splicing. Prediction programs are useful but tend to accu-
mulate errors, especially at the extremities of ORFs that usually
encode signals for secretion. A definitive description of the ORF
complement of the organism is dependent on complete sequen-
cing of the parasite’s transcriptome, a complex, labor-intensive
endeavor, which is not yet complete in S. mansoni; (2) several of
the secreted proteins from multi-cellular organisms will be pro-
duced by internal cells of the parasite and therefore not exposed to
the external environment; (3) schistosomes display a complex life
cycle with very different stages and not all of them occur inside the
mammalian host. Therefore, it is expected that several genes
would have a stage specific expression, meaning that several
external proteins will never be in contact with the host immune
system.
Considering these shortcomings, a direct in silico screening of
the schistosome genome for antigens, using the same criteria as in
prokaryotes and protozoa, might be a time-consuming and rela-
tively inefficient way to identify new vaccine targets. The use of
proteomic information should help one to delineate a subset of
proteins exposed to the host, and/or present in intra-mammalian
stages that may provide a more appropriate starting point for
vaccine trials, as discussed in the next section.
There is evidence that CD4+ T cells of individuals living in
endemic areas who are naturally resistant to schistosomiasis do
respond to S. mansoni antigens such as Sm14 protein [40]. This
raises the possibility that a very recent, high throughput CD4+ T
cell expression screening method [41] could be employed to
identify promising novel S. mansoni vaccine candidates. This
screening method has been successfully used to identify Mycobac-
terium tuberculosis (Mtb) antigens as candidates for a subunit
vaccine against tuberculosis [41]. In S. mansoni, the screening
could use Sm-specific CD4+ T cell lines from naturally resistant
donors, which would be stimulated with different parasite
extracts. These stimulated lines would be used for screening a
S. mansoni cDNA library expressed in Escherichia coli and processed
and presented by autologous dendritic cells from the donors.With
an approach analogous to that of Coler et al. [41], the identity of
novel T cell antigens would be recovered by sequencing the
expression library cDNA clones that encode S. mansoni proteins
causing CD4+ T cell proliferation and IFN-g production.
Using proteomics to determine stage specific proteins
One of the most straightforward uses of proteomics is to compare
the abundance of different proteins along the life cycle of the
parasite. Comparing the abundance of proteins between intra-
mammalian and free-living or intra-molluscan stages would point
towards those with specific functions in the development and
adaptation of the parasite that could be interesting targets for
treatments. Soluble extracts form cercariae, lung worms, adult and
eggs from S. mansoni have been compared using bi-dimensional
(2D) electrophoresis and 24 of the 32 most abundant proteins
detected in those life stages had been previously characterized as a
result of their high immunogenicity, including four previous
vaccine candidates [42]. Subsequently, Liu et al. [33] performed
a sampling of five life stages from S. japonicum (cercariae, hepatic
schistosomula, adults, eggs andmiracidia) and produced extensive
lists with hundreds of proteins with apparent stage specificity. The
information contained on these lists may provide an additional
parameter for selection of promising targets for development of
therapeutics.
In addition, comparisons between protein extracts from adult
male and female were performed to detect gender-specific proteins
in S. japonicum. Proteins involved in development, sexual matura-
tion, signaling and hormone receptors have been described as
differentially displayed in male or female [33,43]. Development
of therapeutic agents targeting the proteins involved in sexual
development or reproduction may have a positive impact in the
control of the disease, considering that blockage of egg laying may
reduce schistosome-induced host liver pathology, as well as impair
transmission of the parasite.
Probing the schistosome surface by proteomics
Exploring the surface of the intra-mammalian stages of schisto-
somes for vaccine and drug targets is a very attractive approach.
One of the reasons for this is that these proteins are easily acces-
sible, meaning that eventual drugs that are developed do not have
to permeate the parasite membrane to reach their targets and that
the antigen is exposed, facilitating antibody binding. In addition,
proteins located at the parasite/host interface are likely to be
associated with mechanisms of escape from the host immune
system or other adaptation to parasitism; and neutralization of
their functions could make the parasite more vulnerable to host
defenses. Therefore, proteomics studies of the schistosome tegu-
ment, which is a syncytial cytoplasmic layer covering the parasite,
have been performed in the hope of describing potential drug
targets and vaccine candidates.
A first approach to determine abundant proteins of the tegu-
ment was developed by Van Balkom et al. [30], using one-dimen-
sional (1D) SDS-PAGE and liquid chromatography coupled with
tandem mass spectrometry (LC–MS/MS) of two samples: (1) a
crude tegument preparation released by freeze-thaw and (2) the
resulting stripped S. mansoni adult worms. Comparison of these
two samples revealed that 43 proteins were detected only in the
tegument, and on the basis of these observations it was proposed
that they were enriched in this tissue [30]. Among those proteins,
we can highlight sperm-coating protein-like (SCP-like) proteins
[23,44] and ATP-diphosphohydrolase [45], which have been pro-
posed to play a role in host parasite interaction, and SGTP-4, which
is implicated in acquisition of glucose from host serum [46].
The strategy of directly using a crude extract, released by freeze-
thaw, for proteomics and comparing its content with the protein
content from stripped worms has some potential drawbacks. It
should be noted that stripped S. mansoni adult wormsmay contain
in their subtegumental cell bodies a number of proteins intended
for exportation to the tegument; therefore, the list of proteins
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shared by tegument and strippedwormsmay include proteins that
in fact perform functions specific to the tegument. For the major-
ity of tegumental proteins, however, the expected concentration
in the total mass of stripped worms would be too low for the
current detection limits ofmass spectrometers, and themajority of
them should remain undetected in this fraction. Another problem
of using crude, non-fractionated tegument extracts is the possible
contamination with subtegumental cell bodies. In fact, detection
in the tegument of proteins related to the protein synthesis path-
way (which is expected to occur at the subtegumental cell bodies,
not at the tegument), such as elongation factor 1-alpha and
eukaryotic translation initiation factor 2-alpha subunit [30] sug-
gests that the tegumental sample may have been in fact contami-
nated with underlying cell bodies.
Amore detailed proteomic study of the S. mansoni tegumentwas
performed by Braschi et al. [29] who divided the tegument into
four fractions on the basis of sequential extractions with buffers of
increasing solubilizing power. These fractions were separated
using 2D electrophoresis, except for the last, insoluble, fraction
that was separated by 1D SDS-PAGE; samples were submitted to
LC–MS/MS, followed by identification by MS/MS. The latter two
fractions obtained by this procedure contained the integral mem-
brane and membrane associated proteins of the tegument [29]. In
those fractions, four different enzymes and seven transporters
have been identified and represent the most interesting targets
owing to their peripheral location. Three out of four enzymes
detected are involved in hydrolysis of organic phosphate com-
pounds. In addition, three different tetraspanins have been
detected in those fractions and were hypothesized to provide
spatial organization for other tegument plasma proteins.
In an attempt to determine which components of the tegu-
ment apical membrane are exposed to the host environment,
Braschi and Wilson [47] performed an incubation of intact
S. mansoni adult worms with two non cell-permeable biotinyla-
tion reagents of variable carbon chain length and later recovered
the biotinylated proteins using a streptavidin column. A total of
24 schistosome proteins were identified and divided into two
groups, one with 9 proteins that were labeled by both reagents
with long and short carbon chain, which must represent the
more exposed proteins in the tegument, and another group with
15 less exposed proteins that were labeled only by the short
carbon chain reagent.
Examining the lists generated by these three studies, it is pos-
sible to detect at least four proteins in common to all of them,
namely an ATP-diphosphohydrolase, a phosphodiesterase, a tetra-
spanin (CD63-like tetraspanin) and a dysferlin. It is possible to
infer that these four tegumentmembrane proteins must have high
abundance to be detected in those three studies. In addition,
several other proteins were detected by at least two of these
approaches, demonstrating their consistency.
Interestingly, two of the tegumental proteins detected in pro-
teomic studies, Sm29 and CD63-like protein tetraspanin (Sm-TSP-
2), have been recently used in independent experiments as vaccine
candidates, causing high reductions of worm burden (>50%) and
of liver egg burden (>60%) in animal models [48,49]. Although
none of these works has used the proteomic data as a starting point
for antigen selection, these results show the potential of tegument
proteins as candidates for vaccine development, highlighting the
importance of those additional tegument proteins newly detected
by proteomics, which were discussed in the previous paragraphs.
A shotgun proteomic approach has also been used to explore the
tegument of adults and hepatic schistosomula of S. japonicum [33]
and 373 tegumental proteins have been identified (134 from adult
females, 58 from adult males, 156 from mixed-sex adults, and 159
from hepatic schistosomula). These included 9 proteins previously
characterized as tegument proteins and components of a Ca2+ ion
signaling pathway that have been point out by the authors as
potential drug targets [33].
Studies were also performed to explore the protein content of
the tegument of the ruminant parasite S. bovis [50]. One of these
studies used 2D immunoblots with infected sheep serum to iden-
tify the most antigenic proteins in the tegument preparation. The
spots from a parallel 2D electrophoresis corresponding to those
regions identified in the 2D immunoblot were excised and 5
different proteins were determined by mass spectrometry. All of
those proteins are soluble and include orthologs of S. mansoni
vaccine candidates glutathione-S-transferase and GAPDH [50].
Considering that the approach that has been utilized shows a very
limited recovery of integral membrane proteins, it is understand-
able that only soluble proteins have been sampled. A more recent
approach used trypsinization of whole adult worms coupled with
LC–MS/MS to detect tegumental proteins exposed in S. bovis [51];
although this methodology is more appropriated to detect the
exposedmembrane proteins in the tegument, the authors reported
mostly cytosolic and cytoskeletal proteins, which suggests leakage
of intra-parasite contents possibly due to damage to the tegument.
In the face of these results, a cautious interpretation of data from
these studies is advisable and further experiments, for example
testing the accessibility of the proteins to non cell-permeable
chemical modifiers, are warranted to indicate whether any of
the proteins detected are, in fact, associated with the tegument.
An additional proteomic study found several host proteins to be
associated with the S. japonicum tegument and other stages of the
parasite life cycle [52]. Although it cannot be ruled out that
detection of some of these proteins can be derived from simple
contamination of samples with host tissue, detection of host
proteins in independent experiments with S. mansoni tegument
[47] and egg hatching fluid [53] reinforce the idea that schisto-
somes might have some mechanism to actively capture host
proteins. It has been proposed that presence of these host proteins
in schistosome tissues could reflect an escape mechanism from
host defense attacks [52]. Identification of the effector proteins for
this mechanism would open the way for development of new
treatments aimed at exposing the parasite to the host defense
system.
Overall, proteomics approaches have so far increased the
amount of information regarding surface-exposed proteins in
schistosomes, especially in the adult worms. Nevertheless, it is
clear that a challenge still lies ahead in terms of better cell-
fractionation and tegument membrane-proteins purification pro-
tocols. Mass spectrometry in the proteomics field is only as good as
the quality of the input protein fractions that are used. In parti-
cular, establishment of novel effective, high-yield fractionation
and purification methods to obtain a homogeneous membrane
fraction from early-stage schistosomula could bring a considerable
improvement in terms of identification of surface-exposed
Drug Discovery Today  Volume 14, Numbers 9/10 May 2009 REVIEWS
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proteins of the parasite along its development from somula to
adult worms inside the human host.
Schistosome secretions
The existence of morphologically distinct intra-mammalian life
stages of the parasite reflects intricate events of interaction with
the human host. It is expected that some of these processes are
mediated by parasite’s secreted proteins and that the analysis of
these products will help to understand and manipulate the
mechanisms of parasitism. In addition, these products are also
in direct contact with the host, being likely candidates for
vaccines. S. mansoni larval secretions have also been the subject
of a proteomic study [54], but are of less interest in the scope of
this review, since the larvae exist only within the mollusc inter-
mediate host, and a possible treatment of molluscs in the open
field to eliminate parasites at this stage would be difficult to
implement.
Cercarial secretions are implicated in the invasion process of
human skin by schistosomes and have been initially studied by
two independent groups. The first study [55] has utilized 1D SDS-
PAGE LC–MS/MS to analyze secretions from stimulated S. mansoni
cercariae, using either human skin lipid stimulation or tail shear-
ing transformation by passages through a syringe; also non-
induced cercariae were used. The authors identified 72, 85 and
15 proteins that were secreted by cercariae submitted to these three
conditions, respectively [55]. In the lipid-stimulated sample 12
glycolytic enzymes, six previous vaccine candidates and three
cercarial elastases were detected [55]. A second study [31] has
utilized S. mansoni cercariae mechanically transformed by vortex-
ing, followed by incubation in culture medium. Released products
were separated by 2D electrophoresis and further analyzed by MS/
MS, being 48 spots associated with protein products. Among these,
the authors identified one novel metalloproteinase, a dipeptidyl
peptidase, a new serine protease inhibitor and four novel immune-
modulators (including the SCP-like protein) [31]. These studies
obtained a diverse list of detected proteins in cercarial secretions,
and because they utilized different approaches to mimic the
process of stimulation of the parasite when invading the human
skin, there is still controversy of which would better represent the
actual secretions from cercariae in its process of invasion of the
human skin (http://www.mcponline.org/cgi/eletters/5/5/835).
A more recent study has performed a proteomic analysis of S.
japonicum cercarial secretions [56]. The authors identified 361
unique proteins in the secretions; fifteen of them were identified
as proteases. Interestingly, the analyses did not identify the pre-
sence of peptide sequences orthologous to S. mansoni cercarial
elastase, the most abundant serine protease enzyme secreted by S.
mansoni cercariae. By contrast, S. japonicum cathepsin B2 (SjCB2),
an ortholog of the S. mansoni cysteine-class cathepsin CB2 was
found; this was the only protease found with potential to degrade
host skin or connective tissue. The authors proposed that cysteine
proteases represent an archetypal tool for tissue invasion among
primitivemetazoa and that the use of serine proteases arose later in
schistosome evolution [56].
More recently, a study of S. mansoni cercariae invasion using
human skin samples has been performed and permitted confir-
mation, bymass spectrometry, of some of the proteins sampled in
the previous proteomics studies, such as the serine protease
inhibitor, SCP-like protein (venom allergen like), GST and glyco-
lytic enzymes in cercarial secretions [57]. The detection of cyto-
solic enzymes in secretions of the parasite suggests that the
acetabular glands of cercariae are holocrine, meaning that cyto-
solic components of the degrading cell will be release by the
gland. This may be an explanatory mechanism to the observed
prominent recognition of some cytosolic antigens by sera of
infected patients [57].
Schistosome eggs are responsible for acute pathogenic responses
that occur in the liver. It is hypothesized that antigens secreted by
eggs induce a granulomatous inflammation and that such
response would be important for excretion of eggs [58]. Secretions
from eggs have been studied by a proteomic approach [32] and a
total of 188 proteins have been identified. Several proteins
involved in cell signaling, redox balance and energy production
have been identified [32]. Several of the detected proteins, such as
histones and cytoskeletal proteins, are not expected to be found in
secretions, raising doubts as to whether the secreted fraction has
been contaminated with leakage products from dead eggs. The
authors utilize the Secretome P program to validate the identifica-
tion of individual proteins, but even with this additional filter the
schistosome histones are still predicted to be secreted. These
findings suggest that perhaps stricter, controlled protein isolation
protocols and analytical parameters are still necessary to deter-
mine the actual set of secreted egg proteins. Further studies of
proteins at the host–parasite egg interface may bring new infor-
mation that would help understanding immune modulation and
the pathology of schistosomiasis.
Schistosome novel proteins
Large-scale sequencing of the S. mansoni and japonicum transcrip-
tomes [23,24] has revealed that over 50% of the transcripts had no
matches in the public sequence databases. A recent re-annotation
revealed that, as of now, approximately 55% of S. mansoni genes
still have no homology outside of the genus [25]. Of the remaining
45% with a homolog, almost half have no functional assignment
after GO analysis. Therefore, informative homology might be as
low as 26% and consequently, three out of four schistosome gene
products have unknown functions [25]. The latter might be a good
starting point for selecting an effective and safe drug or a vaccine
target; one could aim at identifying a protein that has a crucial, so
far unknown function in the parasite that has no homolog in the
human host.
Cellular functions are the result of the coordinated action of
several proteins in macromolecular assemblies and the analysis of
protein–complex composition is an important step in postulating
possible functions for proteins. Mass spectrometry based proteo-
mic tools coupled to tandem affinity purification (TAP) protocols
have proven to be successful in the identification of multicompo-
nent complexes formed under native conditions [59]. The TAP
procedure is an affinity purification technique originally devel-
oped in yeast [60] that produces tagged fusion-protein targets and
enables the purification of the target protein in complex to its
partners under close-to-physiological conditions. Protein complex
composition is then determined by mass spectrometric protein
identification. It has been successfully applied in the analysis of
protein–protein interaction networks in prokaryotic and in eukar-
yotic cells [61,62] and a recent dual-affinity tags modification of
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TAP has improved the procedure specificity and has resulted in a
tenfold increase in protein–complex yield [63]. This allowed pur-
ification of protein complexes that were hitherto not amenable to
TAP, and permitted the use of less starting material, enabling
systematic interaction proteomics projects.
Protein complexes in the cell usually bring together protein
partners in a functional pathway, such as enzymes, their mod-
ulators and regulators. We believe that the field of schistosome
proteomics could aim at finding crucially important, novel drug
and vaccine targets among the proteins of as yet unknown
function that would be determined by TAP or dual-tag TAP to
be part of certain protein complexes. A challenge for this kind of
experiments resides in the development of novel protocols that
would enable a stable transformation of worms with expression
vectors encoding S. mansoni tagged or dual-tagged fusion-
proteins.
Conclusions
Several proteomic studies in schistosomes have been performed in
the past five years in an attempt to identify proteins involved in
crucial processes for the parasite biology. Integration of proteomic
data with those generated bymicroarrays is permitting a change of
paradigm for the proposal of new targets for schistosomiasis
treatment. In fact, databases integrating the molecular informa-
tion for schistosomes are now becoming available [64–66] and
should enable the entire scientific community to elect candidates
for further investigation of their potential as drug targets or
vaccine candidates.
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